-
Most Favored Nation (MFN) Is Altering Biopharma Drug Pricing Forever
Written by
Key Takeaways Target Audiences Innovative Biopharma Executives (US)Executives with assets in early stages of development or nearing US FDA approval, as well as those seeking ex-US launch partners. Big Pharma Executives in ex-US AffiliatesExecutives who are part of the OECD19 and simply trying to understand the pressures being faced by their global and US colleagues,
-
Convergence of US FDA & Drug Pricing
Written by
The FDA, under new leadership, is taking an unprecedented role in drug pricing by linking approval incentives—like Priority Vouchers—to economic impact and Most Favored Nation (MFN) pricing. This blurs the traditional separation between regulatory review and payer negotiation, pressuring prices from day one. These shifts could reshape biopharma valuations, launch strategies, and access dynamics. Companies must closely track policy changes and strengthen development plans that demonstrate meaningful clinical and economic value.
